Additional program funding and expanded program scope, which will double the
Since its inception in
The program has detected several novel strains of SARS-CoV-2 (the virus that causes COVID-19), using different sample types, including nasal swabs collected anonymously from volunteer international travelers arriving at participating airports hosting mobile testing centers in terminals, as well as wastewater samples from airplanes and airport triturators. In
The first phase of multipathogen testing and sequencing in November and
'We are thrilled to have the opportunity to take the TGS program to the next level. Multipathogen biomonitoring expands this critical biosecurity infrastructure for
The program continues to innovate in the space of pathogen genomics and biosecurity by introducing new collection modalities, launching in new locations, and refining the list of target pathogens to provide a clearer picture of what pathogens are circulating in the international travel system. It is supported by robust operational partnership.
'This expansion demonstrates the continued capability of the TGS program and is a further realization of the goal set out by the
'The additional funding of the program allows us to add infrastructure to support new mobile testing centers at
About
Naples Wax Center is a group of upscale skin care boutiques, with three locations currently operating.
XpresCheck is a provider of screening and diagnostic testing in partnership with the
HyperPointe is a leading digital healthcare and data analytics relationship company serving the global healthcare industry.
About
Forward-Looking Statements of
This press release may contain 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words 'believes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'should,' 'seeks,' 'future,' 'continue,' or the negative of such terms, or other comparable terminology. Forward-looking statements relating to expectations about future results or events, including the Company's current plans and expectations relating to the business and operations and future store openings for Naples Wax Center, are based upon information available to XWELL as of today's date and are not guarantees of the future performance of the Company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and other
Forward-Looking Statements of
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the capabilities and potential success of the partnership and Ginkgo's biosecurity platform. These forward-looking statements generally are identified by the words 'believe,' 'can,' 'project,' 'potential,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) volatility in the price of Ginkgo's securities due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting Ginkgo's business, (ii) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (iii) the risk of downturns in demand for products using synthetic biology, (iv) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (v) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (vi) the outcome of any pending or potential legal proceedings against Ginkgo, (vii) our ability to realize the expected benefits from and the success of our Foundry platform programs, (viii) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (ix) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the 'Risk Factors' section of Ginkgo's annual report on Form 10-K filed with the
Conatct:
Email: investors@ginkgobioworks.com
Email: press@ginkgobioworks.com
(C) 2024 Electronic News Publishing, source